Gritstone Oncology, Inc. (NASDAQ: GRTS) was founded in August 2015 and is headquartered in Emeryville, California, USA, with 100 full-time employees (8/31/2018). It is an immuno-oncology company that develops tumor-specific cancer immunotherapies. To combat many types of cancer.
Gritstone Oncology (GRTS):
Gritstone Oncology is an immuno-oncology company that develops tumor-specific cancer immunotherapies to combat multiple cancer types. Gritstone Oncology uses the natural power of the patient’s own immune system to recognize short tumor-specific peptide sequences, called tumor-specific neoantigens (TSNA), present on cancer cells in order to destroy tumor cells.
The goal of Gritstone Oncology is to expand the benefits of immunotherapy by studying patients treated with anti-PD-(L)1 antibodies and other checkpoint inhibitors, using new insights into the immune system’s ability to destroy cancer cells. A key hypothesis that emerged in the field of immuno-oncology is that despite the presence of markers recognizable by the immune system, there are still a large number of cancer patients whose tumors have successfully evaded the immune system (so-called “cold” tumors).
Gritstone Oncology’s method aims to release the natural ability of the patient’s own immune system to recognize short tumor-specific peptide sequences (called tumor-specific neoantigens (TSNA)) present on cancer cells, thereby generating therapeutic immunity in these patients Respond in order to destroy tumor cells.
The importance of TSNA as an immune system target was first recognized in 2014 and 2015 by the two co-founders of Gritstone Oncology, Dr. Timothy Chan and Dr. Naiyer Rizvi, in patients treated with checkpoint inhibitors. Using these insights, the company has built its tumor-specific immunotherapy methods on two key pillars-first, the company’s proprietary Gritstone EDGE™ machine learning platform, which provides us with powerful capabilities that can be extracted from routine tumor biopsies Predict the TSNA present on the patient’s tumor cells; second, the company uses the patient’s TSNA to develop and manufacture effective immunotherapy to drive the patient’s immune system to attack and destroy the tumor.
Gritstone Oncology plans to start phase I/II clinical trials of the company’s first personalized immunotherapy product candidate, GRANITE-001, in the second half of 2018, for the treatment of a variety of common solid tumors.
Gritstone Oncology (GRTS) investment:
Gritstone Oncology, Inc. (NASDAQ:GRTS) submitted its IPO prospectus on 8/23/2018 and listed on NASDAQ on 9/28/2018 with an issue price of US$15.00, issuing 6,071,428 shares, raising US$91.07 million, Goldman Sachs/ Cowen/ Barclays joint underwriting.